Clinical Evidence

Delve into clinical research studies and more

Clinical research lies at the heart of who we are. Vantive uses scientific evidence systematically, and transparently, to inform the development of new state-of-the-art solutions for patients around the world. Here you can find various studies, white papers and articles concerning important topics across the wide range of therapy areas served by Vantive.

HDx therapy enabled by the Theranova Dialyzer
Evaluation of VIE-X Filter Performances vs. Medium Cut-Off Dialyzer and High-Flux Dialyzers on Protein Loss and Inflammatory Status of Chronic Hemodialysis Patients
Visit resource site
HDx therapy enabled by the Theranova Dialyzer
Expanded dialysis (HDX): is there an impact on patient reported symptoms?
Visit resource site
HDx therapy enabled by the Theranova Dialyzer
Expanded Dialysis With Theranova Compared to Conventional High-Flux Hemodialysis: A Randomized Prospective 12-Month Study
Visit resource site
HDx therapy enabled by the Theranova Dialyzer
Expanded Haemodialysis as a Current Strategy to Remove Uremic Toxins
Visit resource site
HDx therapy enabled by the Theranova Dialyzer
Expanded Haemodialysis Therapy of Chronic Haemodialysis Patients Prevents Calcification and Apoptosis of Vascular Smooth Muscle Cells in vitro
Visit resource site
HDx therapy enabled by the Theranova Dialyzer
Expanded Haemodialysis Therapy of Chronic Haemodialysis Patients Prevents Calcification and Apoptosis of Vascular Smooth Muscle Cells in vitro
Visit resource site
HDx therapy enabled by the Theranova Dialyzer
Expanded haemodialysis: from operational mechanism to clinical results
Visit resource site
HDx therapy enabled by the Theranova Dialyzer
Expanded haemodialysis: news from the field
Visit resource site
HDx therapy enabled by the Theranova Dialyzer
Expanded Hemodialysis - A step closer to natural kidneys
Visit resource site
HDx therapy enabled by the Theranova Dialyzer
Expanded Hemodialysis ameliorates uremia-induced impairment of vasculoprotective KLF2 and concomitant proinflammatory priming of endothelial cells through an ERK/AP1/cFOS-dependent mechanism
Visit resource site
HDx therapy enabled by the Theranova Dialyzer
Expanded Hemodialysis and Its Effects on Hospitalizations and Medication Usage: A Cohort Study.
Visit resource site
HDx therapy enabled by the Theranova Dialyzer
Expanded hemodialysis as effective alternative to on-line hemodiafiltration: A randomized mid-term clinical trial
Visit resource site

Important Safety Information

INTENDED USE

The Theranova Dialyzer is indicated for patients with chronic kidney failure who are prescribed intermittent hemodialysis. It provides an expanded solute removal profile with increased removal of various middle molecules (up to 45 kDa) that may play a pathologic role in the uremic clinical syndrome. The Theranova Dialyzer is not intended for hemofiltration or hemodiafiltration therapy. The total extracorporeal blood volume for the Theranova Dialyzer and the set should represent less than 10% of the patient's blood volume.

For single use only.

 

Rx Only. For safe and proper use of the products mentioned herein, please refer to the appropriate Operator’s Manual or Instructions for Use.

 

Vantive, HDx and Theranova are trademarks of Vantive Health LLC or its affiliates.